MANAGEMENT TEAM

Dr. Monaghan has extensive experience in development of new drugs in a wide variety of therapeutic areas.  He has served as co-founder and Chief Development Officer of Thesan Pharma, Vice President of Drug Development at Kadmus Pharma, and Vice President of Clinical Development at TRF Pharmaceuticals.  Earlier in his career, Dr. Monaghan held senior positions in drug development at Serono, Co-Census, and Allergan.

Mr. Smith has served in senior executive positions with a number of public and private biotechnology and pharmaceutical companies, all of which have been involved in the discovery and development of new drugs, in multiple therapeutic areas.  He has been Chief Executive Officer and a director of Virolab, Inc., President, Chief Executive Officer and Director for Genelabs Technologies, Inc. (Nasdaq:GNLB) and Executive Director of Worldwide Business Development at ICN Pharmaceuticals, Inc. (NYSE:ICN), now known as Valeant Pharmaceuticals International.

Dr. Wilcox serves as the Chief of Nephrology and Hypertension, the Director of the Hypertension, Kidney and Vascular Research Center, and the Associate Director of the Angiogenesis Program at the Lombardi Center Institute at Georgetown University. He is also the Vice-Chair for Academic Affairs at the Department of Medicine and the George E. Schreiner Chair of Nephrology at Georgetown University School of Medicine. Dr. Wilcox’s scientific research centers on studies of kidney and microvascular disease in hypertension. Supported by grants from the NIH, his research encompasses experiments on genes, cells and animal models, in addition to clinical research in patients with hypertension and kidney diseases. Dr. Wilcox is the author of more than 250 scientific articles and 2 books on nephrology and hypertension.